Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland by Flint, D J et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin-like growth factor binding proteins initiate cell death and
extracellular matrix remodeling in the mammary gland
Citation for published version:
Flint, DJ, Boutinaud, M, Tonner, E, Wilde, CJ, Hurley, W, Accorsi, PA, Kolb, AF, Whitelaw, CBA, Beattie, J
& Allan, GJ 2005, 'Insulin-like growth factor binding proteins initiate cell death and extracellular matrix
remodeling in the mammary gland' Domestic Animal Endocrinology, vol 29, no. 2, pp. 274-82.,
10.1016/j.domaniend.2005.02.021
Digital Object Identifier (DOI):
10.1016/j.domaniend.2005.02.021
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Domestic Animal Endocrinology
Publisher Rights Statement:
© 2005 Elsevier Inc
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Domestic Animal Endocrinology 29 (2005) 274–282
Insulin-like growth factor binding proteins initiate
cell death and extracellular matrix remodeling
in the mammary gland
D.J. Flint a,∗, M. Boutinaud b, E. Tonner a, C.J. Wilde a, W. Hurley c,
P.A. Accorsi d, A.F. Kolb a, C.B.A. Whitelaw e,
J. Beattie a, G.J. Allan a
a Hannah Research Institute, Ayr KA6 5HL, UK
b UMR Production de lait, INRA, 35590 Saint-Gilles, France
c Department of Animal Sciences, University of Illinois, Urbana, IL 61801, USA
d Dipartimento di Morfoﬁsiologia Veterinaria e Produzioni Animali Facolta‘di Medicina Veterinaria,
Universita ‘di Bologna, Via Tolara di Sopra 50, 40064 Ozzano Emilia (BO), Italia
e Roslin Institute Midlothian, UK
Abstract
We have demonstrated that insulin-like growth factor binding protein-5 (IGFBP-5) production by
mammary epithelial cells increases dramatically during forced involution of the mammary gland in
rats, mice and pigs. We proposed that growth hormone (GH) increases the survival factor IGF-I, whilst
prolactin (PRL) enhances the effects of GH by decreasing the concentration of IGFBP-5, which would
otherwise inhibit the actions of IGFs. To demonstrate a causal relationship between IGFBP-5 and cell
death, we created transgenic mice expressing IGFBP-5, specifically, in the mammary gland. DNA
content in the mammary glands of transgenic mice was decreased as early as day 10 of pregnancy.
Mammary cell number and milk synthesis were both decreased by approximately 50% during the
first 10 days of lactation. The concentrations of the pro-apoptotic molecule caspase-3 was increased
in transgenic animals whilst the concentrations of two pro-survival molecules Bcl-2 and Bcl-x were
both decreased. In order to examine whether IGFBP-5 acts by inhibiting the survival effect of IGF-
I, we examined IGF receptor- and Akt-phoshorylation and showed that both were inhibited. These
studies also indicated that the effects of IGFBP-5 could be mediated in part by IGF-independent
effects involving potential interactions with components of the extracellular matrix involved in tissue
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remodeling, such as components of the plasminogen system, and the matrix metallo-proteinases
(MMPs). Mammary development was normalised in transgenic mice by R3-IGF-I, an analogue of IGF-
I which binds weakly to IGFBPs, although milk production was only partially restored. In contrast,
treatment with prolactin was able to inhibit early involutionary processes in normal mice but was unable
to prevent this in mice over-expressing IGFBP-5, although it was able to inhibit activation of MMPs.
Thus, IGFBP-5 can simultaneously inhibit IGF action and activate the plasminogen system thereby
coordinating cell death and tissue remodeling processes. The ability to separate these properties, using
mutant IGFBPs, is currently under investigation.
© 2005 Elsevier Inc. All rights reserved.
Keywords: Insulin-like growth factor binding protein; IGFBP-5; Mammary gland; Apoptosis; Transgenic; Extra-
cellular matrix; Plasmin
1. Introduction
Cell death is a major determinant of the decline in milk yield in ruminants and a better un-
derstanding of this process clearly offers the opportunity to achieve sustained levels of milk
production over a prolonged lactation. This concept of extended lactation has been exam-
ined in numerous recent studies and is considered to be an economically viable alternative
to the annual lactation cycle, which is widely used. Bovine mammary gland involution is a
key remodeling transformation, which occurs both during and at the end (drying off period)
of lactation and is characterised by a loss of mammary epithelial cells (more moderate than
the intensive loss of cells which occurs during forced involution which has been extensively
studied in the rodent mammary gland). This process is accompanied by extensive prote-
olytic degradation of the extracelluar matrix [1–4]. During this process, cell removal occurs
in the absence of inflammation through the process of programmed cell death or apoptosis
[2–5]. There are several hallmarks of the apoptotic process including caspase activation and
one of the final stages, DNA fragmentation [1].
In dairy cows, genetic selection has dramatically increased two interrelated factors, peak
yield and lactation persistency. Peak yield is determined in part by the number of secretory
cells and in part by the secretory activity per cell. Studies in goats [6] have revealed that
parenchymal cell numbers increase during pregnancy and into early lactation, after which
cell loss is largely responsible for the decline in milk yield, whilst activity per cell is
maintained [7].
2. Prolactin (PRL) and GH are major inﬂuences on cell death in the mammary
gland
The role of PRL on epithelial cell survival has been clearly demonstrated in rodents,
whilst GH seems to have a lesser effect [8]. Reduction in serum prolactin concentrations
resulted in a decrease of milk yield and a loss of around 20–25% of the secretory cell popula-
tion of the mammary gland within 48 h [9]. Conversely, prolactin treatment following litter
removal delayed mouse mammary apoptosis [10], whilst PRL suppression by bromocrip-
tine during lactation also rapidly induced DNA laddering and cell loss, even in the absence
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of milk stasis [11,12]. Although GH plays a less significant role in rodents, induction of
mammary apoptosis by anti-serum to GH in lactating rats [13] demonstrate that it does play
a supporting role [12]. Thus, it has been proposed that (GH) and prolactin play an interac-
tive role in maintaining mammary gland function and cell survival in rodents [11,14–17]
although the precise mechanism of this interaction was unclear until recent observations
provided such a link. In contrast to rodents, GH appears to play the major galactopoietic
role in ruminants. Serum GH concentrations are elevated in the dairy cow during the first
2–3 month post-partum when peak milk yield occurs and decline during late lactation [18].
Numerous studies have shown that administration of GH induces an increase in milk yield
of 10–40% of normal, confirming that GH clearly plays an important role [14,15]. In cow
and goat, GH seems to maintain the number of mammary cells [19] stimulating proliferation
[20] rather than limiting cell death [21,22]. While PRL seems to act directly on mammary
tissue, the effects of GH are considered to be indirect, mediated through stimulation of
IGF-I production [9].
3. GH/IGF-I axis as a cell survival system
IGF-I is predominantly synthesised by liver, but it is now recognised that in many other
tissues it is produced and acts locally, including the mammary stroma. GH treatment in-
creases serum concentrations of IGF-I and activates the expression of both hepatic and
mammary stromal IGF-I mRNA [23,24]. Thus, GH could represent a survival factor for
mammary epithelial cells [7,18]. Considerable data exists to support a role for IGF-I in the
regulation of mammary cell survival both in vitro and in vivo. It has a stimulatory effect on
DNA synthesis and mammary cell proliferation (fibroblast and epithelial cell), casein gene
expression and glucose transport [23,25–27]. In addition, IGF-I can act as a survival factor,
inhibiting apoptosis induced in cultured cells. IGF-I has been shown to promote mammary
epithelial cell survival in vitro in primary cultures [28] and in vivo IGF-I or IGF-II have
been shown to inhibit mammary cell death in transgenic mouse models [29–31].
4. IGF-binding proteins (IGFBPs) inﬂuence IGF actions
The actions of IGF-I are modulated by a family of six proteins, the IGF-binding proteins
or IGFBPs [32]. Their actions are complex, depending upon the tissue, species and concen-
trations of the IGFBP, and in the case of IGFBP-5, its ability to interact with proteins in the
extracellular matrix (ECM), such as heparan sulphate proteoglycans, collagens, fibronectin
and laminin. IGFBPs can inhibit or augment the actions of IGF-I and, in addition, have IGF-
independent effects, particularly in relation to apoptosis. There is evidence that a number of
IGF binding proteins, as well as IGFs themselves, are synthesised by the mammary epithe-
lial cells. During the process of lactational involution there is a 4-fold increase in IGFBP-2
mRNA and dramatic 6- and 50-fold increases in the expression of IGFBP-4 and IGFBP-5
message, respectively, along with a significant increase in IGFBP-5 protein, all within 48 h
after weaning in rats [13,33,34] and mice [35]. When the mammary gland ceases to produce
milk it undergoes massive apoptosis resulting in a return of the gland to a rudimentary state.
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We showed that the mammary epithelium secretes increased concentrations of IGFBP-5 at
this time, which we proposed served to inhibit IGF-mediated cell survival. Furthermore,
we provided the first mechanistic explanation for the interactive effects of GH and PRL,
which act in concert to support mammary gland development through a process involving
stimulation of IGF-I synthesis by GH and inhibition of IGFBP-5 production by PRL [36].
In addition, two recent studies have shown that part of the effect of prolactin may be to
increase IGF-II production in the mammary gland [37,38].
IGFBP-5 expression is also increased in the involuting thyroid [39], in ovarian follicles
undergoing atresia [40] and in regressing prostate after androgen withdrawal [41]. We thus
proposed that the secretion of IGFBP-5 is involved in the initial stages of apoptosis in many
tissues by inhibiting IGF-I-mediated cell survival [13]. We subsequently showed that this
increase in IGFBP-5 during mammary involution also occurs in mice during forced involu-
tion and in pigs following weaning at day 21 of lactation (our unpublished observations). In
addition, we have demonstrated an increase in an unidentified IGFBP in the milk of sheep
48 h after weaning of lambs. Sejrsen et al. [42] also described increases in both IGFBP-4
and IGFBP-5 during the drying off period in cattle. A role for IGFBP-5 in bovine mammary
apoptosis was also evident from in vitro studies of mammosphere cultures [42]. Around
day 3 of culture, there is increased DNA laddering and DNA fragmentation in cells within
the core of the mammosphere, which die in order to allow lumen formation and vectorial
secretion of milk proteins. This event was preceded by an increase in IGFBP-5 secretion
into the medium [43]. In a second study involving explants of bovine mammary tissue,
we cultured explants in the presence of cortisol, 17-estradiol, progesterone, insulin, GH,
PRL and IGF-I. We omitted PRL, GH and IGF-I from the cultures and determined any
subsequent changes in both the levels of apoptosis by evaluation of DNA laddering and
IGFBP-5 message levels by RT-PCR. The results showed a high level of DNA laddering
and an increase in IGFBP-5 mRNA content in mammary explants cultured under these
conditions [44]. This offers further evidence of a close and direct correlation between levels
of apoptosis and IGFBP-5 mRNA expression and confirms the importance of this binding
protein in the initiation of programmed cell death in bovine mammary tissue.
5. IGFs and cancer: a causal relationship
IGF-I is a survival factor for many cell types and could, thus, be a determining factor
in tumour growth, when cell death programmes are overridden. The hypothesis that IGF-
I is a tumour promoter has been proposed as a result of several epidemiological studies,
which have demonstrated that individuals with high plasma IGF-I concentrations have an
increased risk of developing cancers of the mammary gland, intestine and prostate gland
[45–48]. This association between IGFs and cancer risk is even stronger when corrected for
concentrations of circulating IGFBPs. Thus, cancer risk is greatest for individuals with high
IGF-I and low IGFBP-3 concentrations. Support for a role of IGFBPs as tumour suppressors
also comes from demonstrations that agents which are effective in tumour therapy, anti-
oestrogens, retinoids and Vitamin D analogues, stimulate IGFBP production by cells in
vitro [49–51]. Furthermore, phosphatase and tensin homologue (PTEN), the second most
commonly mutated tumour suppressor, when expressed as a transgene in the mammary
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gland, leads to increased apoptosis and a 25-fold increase in IGFBP-5 [52]. Thus, PTEN as
a phosphatidyl-inositol trisphosphate (PIP-3) phosphatase inhibits intracellular signalling
via the IGF/PI3-kinase/Akt pathway and inhibits extracellular IGF signalling indirectly
by increasing IGFBP-5 secretion. This combination of epidemiological, clinical and basic
scientific data has led to the suggestion that IGFBPs could be used to inhibit tumour cell
proliferation.
6. IGFBP-5 is a causal factor in cell death
The issue of a causal relationship between IGFBP-5 synthesis and cell death in the mam-
mary gland has not been possible in ruminants because of the lack of sufficient quantities of
the protein or the routine application of transgenesis, and thus, not surprisingly, the demon-
stration of causality between IGFBP-5 and cell death has been exclusively achieved in
rodent models. Several studies have examined the effects of exogenous IGFBP-5, including
in vitro and in vivo approaches, and we have also developed a transgenic model examin-
ing the effects of over-expression of IGFBP-5 using a mammary-specific promoter. Streuli
and co-workers [53] have demonstrated that addition of exogenous IGFBP-5 or IGFBP-
3 to mammary epithelial cells suppresses IGF-I-mediated survival, resulting in three-fold
greater apoptosis in cells compared to the rates seen with IGF-I alone, involving decreased
phosphorylation of Akt (a downstream signalling molecule for IGF-I) and the forkhead
transcription factor, FKHRL1. Recent studies using human breast cancer cells have also re-
vealed that IGFBP-5 can inhibit their growth both in vivo and in vitro [54]. Administration
of IGFBP-5 during late pregnancy resulted in impaired development of mammary alveoli
and reduced invasion of the mammary fat pad, indicative of increased rates of apoptosis
[55]. Perhaps the most convincing evidence for this role of IGFBP-5 comes from our studies
in transgenic mice expressing IGFBP-5 in the mammary gland, using a mammary-specific
promoter, -lactoglobulin (BLG) [56]. We found that the DNA content in the mammary
glands of transgenic mice was decreased by day 10 of pregnancy and mammary cell number
and milk synthesis were both decreased by approximately 50% during the first 10 days of
lactation. Around parturition the concentrations of the pro-apoptotic molecule caspase-3
and of plasmin (an indicator of the breakdown of the ECM) were both increased, whereas
the concentrations of two pro-survival molecules, Bcl-2 and Bcl-xL were significantly re-
duced. The bcl-2 proteins are a family of proteins involved in the response to apoptosis.
Some of these proteins (such as bcl-2 and bcl-XL) are anti-apoptotic, while others (such
as Bad or Bax) are pro-apoptotic. The pro-apoptotic bcl-2 proteins are often found in the
cytosol where they act as sensors of cellular damage or stress. Following cellular stress they
relocate to the surface of the mitochondria, where the anti-apoptotic proteins are located.
This interaction between pro- and anti-apoptotic proteins disrupts the normal function of
the anti-apoptotic bcl-2 proteins and can lead to the formation of pores in the mitochondria
and the release of cytochrome C and other pro-apoptotic molecules from the intermembrane
space. This in turn leads to the formation of the apoptosome and the activation of caspases.
Furthermore, the effects of IGFBP-5 on DNA content could be completely prevented
by treatment with R3-IGF-I, an analogue of IGF-I, which binds with very low affinity to
IGFBP-5. Despite this, the decrease in milk yield was only partially prevented. All of these
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findings are strongly consistent with a pro-apoptotic effect of IGFBP-5, which is mediated
principally by inhibition of IGF actions.
7. ECM remodeling—a role for IGFBP-5
During mammary involution degradation of the ECM occurs via activation of plasmino-
gen and the matrix-metallo proteinases. IGFBPs also interact with a variety of molecules in
the ECM and these interactions may influence the actions of the binding proteins. Interac-
tions of cells with the ECM forms a crucial regulatory system, which when disrupted (such
as during activation of matrix-metallo proteinases, MMPs), can lead to increased migratory
activity and potential development of metastases. Mutant IGFBPs, which are either unable
to bind to the ECM or to IGFs, have recently been developed in our laboratory to investi-
gate these interactions in relation to biological function [57–60]. We have demonstrated in
IGFBP-5 transgenic mice that plasminogen is cleaved to plasmin during mammary gland
development at a time when plasmin generation is normally suppressed [56]. Plasminogen
activators, tissue-type plasminogen activator and urokinase plasminogen activator (tPA and
uPA, respectively), generate plasmin whereas plasminogen activator inhibitor-1 (PAI-1),
which inhibits the proteolytic activation of plasminogen to plasmin by both tPA and uPA.
Previously, others have demonstrated that IGFBP-5 is able to bind directly to PAI-1 with
high affinity [61], and we have recently demonstrated that IGFBP-5 can inhibit the ac-
tions of PAI-1 and thus could influence both cell survival and tissue remodeling processes
(unpublished results).
In conclusion, mammary cell survival is reflected by a balance between the survival
effects of IGF-I, in part driven by GH and the death-inducing effects of IGFBPs. Several
species exhibit increases in IGFBP production in the mammary gland during the natural
involutionary process that occurs at the end of lactation and we have demonstrated, using
exogenous IGFBPs and by expressing IGFBP-5 as a transgene in the mammary gland that
IGFBP-5 can indeed induce apoptotic cell death in mammary epithelial cells. Furthermore,
we identified a novel mechanism by which IGFBP-5 activates plasmin generation and thus
potentially initiates the proteolytic cascade, which results in remodeling of the extracellular
matrix. This provides an intriguing mechanism whereby the dying epithelial cell produces
a suicide protein, which serves to inhibit its two principal survival signals, growth factor
and integrin-mediated events. Such a mechanism may provide important protection against
the inappropriate disruption of cell anchorage (by activation of proteases) in the presence of
sustained growth factor survival signals, an event which would favour metastatic processes.
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